NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Forecast, Price & News $0.57 -0.02 (-3.39%) (As of 01:12 PM ET) Add Compare Share Share Today's Range$0.57▼$0.6050-Day Range$0.48▼$0.6352-Week Range$0.46▼$10.39Volume174,148 shsAverage Volume678,911 shsMarket Capitalization$4.13 millionP/E RatioN/ADividend YieldN/APrice Target$46.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Kiora Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7,763.2% Upside$46.00 Price TargetShort InterestHealthy3.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.74) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 stars 3.5 Analyst's Opinion Consensus RatingKiora Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.00, Kiora Pharmaceuticals has a forecasted upside of 7,763.2% from its current price of $0.59.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.75% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently decreased by 30.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KPRX. Previous Next 3.6 News and Social Media Coverage News SentimentKiora Pharmaceuticals has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kiora Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 13.92% of the stock of Kiora Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kiora Pharmaceuticals are expected to grow in the coming year, from ($1.74) to ($0.71) per share.Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kiora Pharmaceuticals (NASDAQ:KPRX) StockKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Read More KPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPRX Stock News HeadlinesOctober 3, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaSeptember 21, 2023 | finance.yahoo.comKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsOctober 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 18, 2023 | finance.yahoo.comKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis PigmentosaSeptember 14, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis PigmentosaSeptember 1, 2023 | finance.yahoo.comKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27August 29, 2023 | finance.yahoo.comKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal DiseasesAugust 24, 2023 | finance.yahoo.comIs Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation AnalysisOctober 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 23, 2023 | marketwatch.comKiora Pharmaceuticals Shares Up 18% on Patents Covering Ocular Delivery of MoleculesAugust 23, 2023 | markets.businessinsider.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?August 23, 2023 | finance.yahoo.comKiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious UveitisAugust 22, 2023 | finance.yahoo.comKiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness ProgramAugust 16, 2023 | finance.yahoo.comKiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceAugust 8, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development ProgressAugust 3, 2023 | finance.yahoo.comKiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia TreatmentAugust 1, 2023 | finance.yahoo.comBiotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of DirectorsJuly 21, 2023 | investorplace.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?July 5, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic DiseaseJuly 5, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic DiseaseJune 22, 2023 | marketwatch.com8-K: KIORA PHARMACEUTICALS INCJune 20, 2023 | finance.yahoo.comLife Science Investor Forum Agenda Announced for June 22ndJune 15, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201June 15, 2023 | finance.yahoo.comKiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201June 14, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present at Upcoming Investor ConferencesJune 6, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionJune 2, 2023 | baystreet.caKiora Heralds Public OfferingSee More Headlines Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Company Calendar Last Earnings8/08/2023Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPRX CUSIPN/A CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$46.00 High Stock Price Forecast$119.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+7,930.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.39% Return on Assets-58.70% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.79 Sales & Book Value Annual Sales$10,000.00 Price / Sales415.28 Cash FlowN/A Price / Cash FlowN/A Book Value$9.99 per share Price / Book0.06Miscellaneous Outstanding Shares7,250,000Free Float7,179,000Market Cap$4.15 million OptionableNot Optionable Beta-0.24 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Brian M. Strem Ph.D. (Age 43)Pres, CEO & Director Comp: $464.93kMs. Melissa Tosca CPA (Age 43)Exec. VP of Fin. Comp: $282.28kDr. Eric J. Daniels M.B.A. (Age 50)M.D., Chief Devel. Officer Comp: $371.47kDr. Stefan Sperl Ph.D.Exec. VP of CMC & OperationsKey CompetitorsLixte BiotechnologyNASDAQ:LIXTBiondVax PharmaceuticalsNASDAQ:BVXVTransCode TherapeuticsNASDAQ:RNAZProtagenic TherapeuticsNASDAQ:PTIXAgile TherapeuticsNASDAQ:AGRXView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 250,258 shares on 8/15/2023Ownership: 12.365%View All Institutional Transactions KPRX Stock - Frequently Asked Questions Should I buy or sell Kiora Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPRX shares. View KPRX analyst ratings or view top-rated stocks. What is Kiora Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price objectives for Kiora Pharmaceuticals' shares. Their KPRX share price forecasts range from $7.00 to $119.00. On average, they anticipate the company's share price to reach $46.00 in the next twelve months. This suggests a possible upside of 7,930.7% from the stock's current price. View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts. How have KPRX shares performed in 2023? Kiora Pharmaceuticals' stock was trading at $3.43 at the beginning of 2023. Since then, KPRX shares have decreased by 83.3% and is now trading at $0.5728. View the best growth stocks for 2023 here. Are investors shorting Kiora Pharmaceuticals? Kiora Pharmaceuticals saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 252,600 shares, a decrease of 30.6% from the August 31st total of 364,200 shares. Based on an average daily volume of 325,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 3.8% of the company's stock are sold short. View Kiora Pharmaceuticals' Short Interest. When is Kiora Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our KPRX earnings forecast. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) released its earnings results on Tuesday, August, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.28. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals's stock reverse split on the morning of Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What is Kiora Pharmaceuticals' stock symbol? Kiora Pharmaceuticals trades on the NASDAQ under the ticker symbol "KPRX." How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kiora Pharmaceuticals' stock price today? One share of KPRX stock can currently be purchased for approximately $0.57. How much money does Kiora Pharmaceuticals make? Kiora Pharmaceuticals (NASDAQ:KPRX) has a market capitalization of $4.15 million and generates $10,000.00 in revenue each year. How can I contact Kiora Pharmaceuticals? Kiora Pharmaceuticals' mailing address is 271 Waverley Oaks Rd Ste 108, Waltham, Massachusetts 02452-8475. The official website for the company is eyegatepharma.com. The company can be reached via phone at (781) 788-9043 or via email at cdavis@lifesciadvisors.com. This page (NASDAQ:KPRX) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.